Mersana Net Working Capital from 2010 to 2024

MRSN Stock  USD 2.21  0.31  12.30%   
Mersana Therapeutics Net Working Capital yearly trend continues to be very stable with very little volatility. Net Working Capital is likely to drop to about 143.9 M. During the period from 2010 to 2024, Mersana Therapeutics Net Working Capital quarterly data regression pattern had sample variance of 3466.7 T and median of  85,662,000. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
150.4 M
Current Value
143.9 M
Quarterly Volatility
58.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mersana Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mersana Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 11.6 M, Depreciation And Amortization of 1.1 M or Interest Expense of 4.3 M, as well as many indicators such as Price To Sales Ratio of 6.94, Dividend Yield of 0.0 or PTB Ratio of 7.66. Mersana financial statements analysis is a perfect complement when working with Mersana Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Mersana Therapeutics Correlation against competitors.
To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.

Latest Mersana Therapeutics' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Mersana Therapeutics over the last few years. It is Mersana Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mersana Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Mersana Net Working Capital Regression Statistics

Arithmetic Mean110,627,349
Geometric Mean88,999,679
Coefficient Of Variation53.22
Mean Deviation45,178,865
Median85,662,000
Standard Deviation58,879,074
Sample Variance3466.7T
Range223.7M
R-Value0.56
Mean Square Error2567.1T
R-Squared0.31
Significance0.03
Slope7,358,852
Total Sum of Squares48534.4T

Mersana Net Working Capital History

2024143.9 M
2023150.4 M
2022227.7 M
2021141.4 M
2020228.6 M
201977.3 M
20184.9 M

About Mersana Therapeutics Financial Statements

Mersana Therapeutics investors utilize fundamental indicators, such as Net Working Capital, to predict how Mersana Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Working Capital150.4 M143.9 M

Pair Trading with Mersana Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Mersana Stock

  0.61DMAC DiaMedica TherapeuticsPairCorr

Moving against Mersana Stock

  0.87VALN Valneva SE ADRPairCorr
  0.57VCNX VaccinexPairCorr
  0.53ME 23Andme HoldingPairCorr
  0.53DTIL Precision BioSciencesPairCorr
  0.49DRMA Dermata TherapeuticsPairCorr
The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.
The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Mersana Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mersana Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mersana Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mersana Therapeutics Stock:
Check out the analysis of Mersana Therapeutics Correlation against competitors.
To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.85)
Revenue Per Share
0.247
Quarterly Revenue Growth
(0.79)
Return On Assets
(0.26)
Return On Equity
(2.13)
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.